PDLIM1 and esophageal squamous cell carcinoma: Studies have shown that I rubescens has a therapeutic effect on esophageal squamous cell carcinoma by inhibiting the protein expression of LASP1 (LIM and SH3 protein 1) and PDLIM1 (recombinant PDZ And LIM domain protein 1),[101] and selectively producing cytotoxicity on p35 mutant cells.[117] Interestingly, in the concomitant drugs for this cancer, Getuximab enhances Oridonin ‘s induction of cell apoptosis,[118] while Oridonin can enhance the effect of cisplatin.[117] These 3 drugs may be used in combination.